The scientific goals of the Hollings Cancer Center Cancer Biology Program are to identify novel genomic and genetic alterations that play causal roles in cancer development and to study genes, proteins and signaling pathways that mediate the altered phenotypes of cancer cells.
Professor and Chair of Biochemistry & Molecular Biology | College of Medicine
Dr. Philip H. Howe holds the Hans and Helen Koebig Chair in Oncology. He has an outstanding record of scientific achievements, having maintained continuous funding for over 27 years. His research is focused on transforming growth factor beta signaling pathways in mediating the epithelial-mesenchymal transition in epithelium and apoptosis in developing B-lymphocytes.
Dr. Stephen P. Ethier and his laboratory have studied the mechanisms by which oncogenes transform human mammary epithelial cells and play a role in breast cancer development. His research interests are in the mechanisms by which the HER-2 oncogene regulates the expression of transformed phenotypes in breast cancer cells and the role of EGFR signaling in triple negative breast cancers, particularly those in which EGFR is activated via an autocrine loop involving one of its ligands, amphiregulin. Dr. Ethier and his team have also developed a strong interest in breast cancer genomics and understanding the oncogenes that are present on the 8p11 amplicon, which occurs in approximately 15% of human breast cancers and is exclusively seen in the most aggressive luminal B type breast cancers.